Biomea Fusion Inc is a biotechnology business based in the US. Biomea Fusion shares (BMEA) are listed on the NASDAQ and all prices are listed in US Dollars. Biomea Fusion employs 57 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $11.15 |
|---|---|
| 52-week range | $2.84 - $16.28 |
| 50-day moving average | $6.32 |
| 200-day moving average | $7.86 |
| Wall St. target price | $19.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.85 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $11.15 from 2022-07-01
| 1 week (2022-06-27) | -7.32% |
|---|---|
| 1 month (2022-06-03) | 108.80% |
| 3 months (2022-04-05) | 142.92% |
| 6 months (2022-01-05) | 49.26% |
| 1 year (2021-07-02) | -26.64% |
|---|---|
| 2 years (2020-07-01) | N/A |
| 3 years (2019-07-01) | N/A |
| 5 years (2017-07-01) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -27.8% |
| Return on equity TTM | -47.19% |
| Profit margin | 0% |
| Book value | $5.65 |
| Market capitalisation | $325.2 million |
TTM: trailing 12 months
We're not expecting Biomea Fusion to pay a dividend over the next 12 months.
You may also wish to consider:
Biomea Fusion, Inc. , a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.